Back to Directory Dayana Leon Email dayanaleon@westat.com Phone 240-936-3017 Institution Westat Address Westat 1600 Research Boulevard Rockville, MD 20850 USA Request an Update Affiliated Studies IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Treatment Study Status In Development IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Treatment Study Status Closed to Accrual
IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Treatment Study Status In Development
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Treatment Study Status Closed to Accrual